Related Experiment Video

Updated: Jan 10, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

6.3K

Comment on: Leukoencephalopathy, a Frequent Complication After High-Dose Methotrexate in Treatment of Osteosarcoma.

Ian J Cohen1

  • 1The Rina Zaizov Department of Pediatric Hematology Oncology, the Schneider Children's Hospital of Israel, Petah Tikvah, and the Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Pediatric Blood & Cancer
|November 24, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.5K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.6K

Related Experiment Videos

Last Updated: Jan 10, 2026

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease
07:17

A Murine Ommaya Xenograft Model to Study Direct-Targeted Therapy of Leptomeningeal Disease

Published on: January 29, 2021

6.3K
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
07:14

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

Published on: May 23, 2025

1.5K
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

Articles linked to this work by shared authors, journal, and citation graph.

Delayed Rewarming Thrombocytopenia (DRT): A Temperature-Dependent Platelet Aggregation Disorder.

Hematology reports·2026

Delayed Rewarming Thrombocytopenia Not Disseminated Intravascular Coagulation, is the Cause of Rewarming Deaths in Neonatal Cold Injury.

Journal of pediatric hematology/oncology·2025

After 75 Years of Methotrexate, Can Treatment Results Be Improved With Appropriate Folinic Acid Rescue?

Pediatric blood & cancer·2025

A Comprehensive Review of Neuropsychologic Studies Supports the Concept That Adequate Folinic Acid Rescue Prevents Post Methotrexate Neurotoxicity.

Journal of pediatric hematology/oncology·2023

SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.

Cancer chemotherapy and pharmacology·2019

Neurotoxicity after high-dose methotrexate (MTX) is adequately explained by insufficient folinic acid rescue.

Cancer chemotherapy and pharmacology·2017

Pain Management After Pediatric Hematopoietic Cell Transplantation: A Narrative Review of Pain Phenotypes, Assessment, and Multimodal Care.

Pediatric blood & cancer·2026

A Three-Component Immune Framework Stratifies Treatment Response and Escalation in Pediatric Hemophagocytic Lymphohistiocytosis: A Prospective Single-Center Cohort Study.

Pediatric blood & cancer·2026

Safety and Effectiveness of a High-Dose, Tailored Tissue Plasminogen Activator Therapy Protocol: A Joint Pediatric Hematology and Cardiac ICU Quality Improvement Initiative Analysis.

Pediatric blood & cancer·2026

Pain in Children and Adolescents With Low-Flow Vascular Malformation and Its Relation to Thrombosis.

Pediatric blood & cancer·2026

Global Efforts to Reduce Paediatric Cancer Care Disparities in Radiotherapy: A Decade Change.

Pediatric blood & cancer·2026

Provider and Parent Perspectives on Prioritizing the "Asking and Monitoring" Pediatric Cancer Psychosocial Standards of Care.

Pediatric blood & cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us